Table S1 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Baseline characteristics of ONC201-treated H3K27M-DMG patients included in analysis.
Me gusta
Guardar
Compartir
Me gusta
Guardar
Compartir
Table S1 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways | Synapse